Guardian Pharmacy Services, Inc. (GRDN) Key Metrics
GRDN valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $2.50B
- Enterprise value
- $2.69B
- P/E (TTM)
- 38.3
- Forward P/E
- 30.2
- PEG ratio
- —
- Price / sales
- 1.7
- Price / book
- 11.2
- EV / EBITDA
- 22.4
- Dividend yield
- —
- Beta
- 0.02
GRDN key metrics, 2018–2025
Fiscal year ended December 31, 2025 · U.S. dollarsGRDN valuation Price multiples at each fiscal year-end price.
GRDN returns How much profit the business earns on the capital it uses.
GRDN per-share figures Results divided by the shares outstanding at year-end.
GRDN financial health Debt, liquidity and how easily interest is covered.
GRDN efficiency & capital use Working capital cycle and where the cash goes.
GRDN valuation history
GRDN returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
GRDN debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
GRDN cash returned to shareholders
GRDN price vs earnings per share
GRDN key metrics
2018–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||
| Market capitalization | $1.90B | $1.26B | — | — | — | — | — | — |
| Enterprise value | $1.88B | $1.28B | — | — | — | — | — | — |
| P/E ratio | 38.7 | — | — | — | — | — | — | — |
| Price / sales | 1.3 | 1.0 | — | — | — | — | — | — |
| Price / book | 9.3 | 8.8 | — | — | — | — | — | — |
| Price / free cash flow | 23.6 | 30.2 | — | — | — | — | — | — |
| Price / operating cash flow | 19.0 | 21.7 | — | — | — | — | — | — |
| EV / sales | 1.3 | 1.0 | — | — | — | — | — | — |
| EV / EBITDA | 19.5 | — | — | — | — | — | — | — |
| EV / free cash flow | 23.2 | 30.8 | — | — | — | — | — | — |
| Earnings yield | 2.6% | −6.9% | — | — | — | — | — | — |
| Free cash flow yield | 4.2% | 3.3% | — | — | — | — | — | — |
| Dividend yield | 0.0% | 2.8% | — | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | 1.5% | 7.2% | — | — | — | — | — | — |
| Share price at fiscal year-end | $30.09 | $20.26 | — | — | — | — | — | — |
| Per share | ||||||||
| Revenue per share | $22.89 | $19.81 | $17.19 | $14.94 | $13.02 | $12.10 | $11.48 | $9.87 |
| Earnings per share | $0.78 | −$1.41 | $0.39 | $0.58 | $0.27 | $0.33 | $0.36 | $0.24 |
| Operating cash flow per share | $1.58 | $0.93 | $1.16 | $0.80 | $0.96 | $0.86 | $0.92 | $0.72 |
| Free cash flow per share | $1.28 | $0.67 | $0.92 | $0.52 | $0.81 | $0.73 | $0.68 | $0.55 |
| Cash per share | $1.04 | $0.08 | $0.01 | $0.01 | $0.25 | $0.11 | $0.00 | $0.04 |
| Book value per share | $3.25 | $2.30 | $0.46 | $0.70 | $0.39 | $0.63 | $0.94 | $0.56 |
| Tangible book value per share | $1.70 | $0.94 | −$0.65 | −$0.46 | −$0.79 | −$0.54 | −$0.16 | −$0.62 |
| Dividends per share | $0.00 | $0.58 | $0.63 | $0.51 | $0.29 | $0.18 | $0.56 | $0.46 |
| Capex per share | $0.31 | $0.26 | $0.24 | $0.28 | $0.15 | $0.14 | $0.24 | $0.16 |
| Debt per share | $0.59 | $0.49 | $1.14 | $1.04 | $0.90 | $0.97 | $0.94 | $0.72 |
| Shares outstanding | 63.3M | 62.0M | 60.8M | 60.8M | 60.8M | 60.8M | 60.8M | 60.8M |
| Change in shares outstanding | +2.1% | +1.9% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Returns & profitability | ||||||||
| Return on equity (ROE) | 28.3% | −102.2% | 67.4% | 106.3% | 52.3% | 41.8% | 47.8% | 43.1% |
| Return on invested capital (ROIC) | 34.3% | −37.5% | 32.1% | 48.6% | 30.8% | 24.7% | 28.4% | 27.1% |
| Return on assets (ROA) | 13.4% | −29.5% | 9.1% | 14.4% | 7.2% | 9.6% | 11.5% | 8.1% |
| Return on tangible assets | 15.7% | −36.9% | 11.8% | 19.1% | 9.9% | 13.6% | 16.8% | 13.3% |
| Free cash flow margin | 5.6% | 3.4% | 5.4% | 3.5% | 6.2% | 6.0% | 6.0% | 5.6% |
| Income quality (OCF / net income) | 2.04 | — | 2.96 | 1.37 | 3.59 | 2.64 | 2.58 | 2.98 |
| Financial health | ||||||||
| Total debt | $37.1M | $30.1M | $69.2M | $63.0M | $55.0M | $58.8M | $57.1M | $43.7M |
| Cash & short-term investments | $65.6M | $4.7M | $752,000 | $607,000 | $15.0M | $6.4M | $275,000 | $2.3M |
| Net debt | −$28.5M | $25.5M | $68.4M | $62.4M | $40.0M | $52.4M | $56.8M | $41.5M |
| Debt / equity | 0.18 | 0.21 | 2.45 | 1.47 | 2.30 | 1.53 | 1.00 | 1.28 |
| Debt / assets | 0.09 | 0.09 | 0.26 | 0.25 | 0.23 | 0.27 | 0.29 | 0.24 |
| Net debt / EBITDA | −0.30 | — | 1.16 | 0.92 | 0.86 | 1.07 | 1.15 | 1.08 |
| Current ratio | 1.38 | 1.05 | 0.94 | 1.07 | 1.00 | 1.09 | 1.00 | 1.24 |
| Quick ratio | 1.11 | 0.77 | 0.67 | 0.70 | 0.71 | 0.72 | 0.66 | 0.82 |
| Interest coverage | 133.7 | -19.2 | 14.3 | 27.0 | 18.4 | 14.9 | 15.1 | 13.6 |
| Working capital | $60.9M | $7.9M | −$8.4M | $8.0M | $331,000 | $7.5M | −$111,000 | $16.0M |
| Invested capital | $177.3M | $168.1M | $96.6M | $105.1M | $64.0M | $90.9M | $113.9M | $75.5M |
| Tangible asset value | $119.7M | $65.8M | −$8.2M | $5.4M | −$18.4M | −$4.5M | −$10.0M | −$3.6M |
| Net current asset value | $26.9M | −$18.8M | −$81.7M | −$60.2M | −$70.7M | −$57.0M | −$49.4M | −$32.6M |
| Graham number | $7.54 | — | $2.02 | $3.03 | $1.54 | $2.16 | $2.75 | $1.74 |
| Graham net-net per share | −$0.49 | −$1.18 | −$2.21 | −$1.77 | −$1.80 | −$1.55 | −$1.37 | −$1.02 |
| Capital allocation | ||||||||
| Dividends paid | $0 | $35.8M | $38.4M | $30.8M | $17.4M | $10.8M | $34.3M | $28.0M |
| Share buybacks (net) | $29.0M | $55.2M | $0 | — | — | — | — | — |
| Dividend payout ratio | 0.0% | — | 160.7% | 87.0% | 106.4% | 54.2% | 157.8% | 190.7% |
| Dividends + buybacks / free cash flow | 36.0% | 218.6% | 68.3% | 97.0% | 35.3% | 24.4% | 82.5% | 83.1% |
| Capex / revenue | 1.4% | 1.3% | 1.4% | 1.8% | 1.2% | 1.1% | 2.1% | 1.7% |
| Capex / operating cash flow | 19.5% | 28.2% | 20.6% | 34.6% | 15.9% | 15.9% | 25.9% | 22.9% |
| Capex / depreciation | 0.88 | 0.83 | 0.80 | 1.01 | 0.56 | 0.48 | 0.92 | 0.76 |
| Stock-based compensation / revenue | 1.0% | 10.7% | −0.6% | −0.4% | 1.6% | 0.4% | 0.3% | 1.0% |
| SG&A / revenue | 15.2% | 24.7% | 16.0% | 0.4% | 16.6% | 13.9% | 14.0% | 14.6% |
| Efficiency | ||||||||
| Days sales outstanding | 25.0 | 25.9 | 25.3 | 24.7 | 23.3 | 24.8 | 26.6 | 29.0 |
| Days of inventory on hand | 13.1 | 14.3 | 17.0 | 18.8 | 18.8 | 19.5 | 19.2 | 21.1 |
| Days payables outstanding | 34.2 | 34.9 | 35.7 | 36.0 | 34.1 | 33.6 | 33.7 | 36.3 |
| Cash conversion cycle (days) | 4.0 | 5.4 | 6.7 | 7.5 | 7.9 | 10.7 | 12.2 | 13.7 |
| Receivables turnover | 14.58 | 14.09 | 14.42 | 14.77 | 15.68 | 14.72 | 13.71 | 12.60 |
| Payables turnover | 10.67 | 10.47 | 10.24 | 10.13 | 10.69 | 10.87 | 10.83 | 10.04 |
| Inventory turnover | 27.81 | 25.47 | 21.44 | 19.40 | 19.40 | 18.74 | 18.98 | 17.33 |
| Asset turnover | 3.95 | 4.15 | 3.97 | 3.70 | 3.49 | 3.55 | 3.69 | 3.30 |
| Average receivables | $99.4M | $87.2M | $72.5M | $61.5M | $50.5M | $50.0M | $50.9M | $47.7M |
| Average payables | $109.3M | $94.0M | $81.9M | $71.4M | $59.0M | $54.2M | $51.2M | $47.5M |
| Average inventory | $42.0M | $38.6M | $39.1M | $37.3M | $32.5M | $31.4M | $29.2M | $27.5M |
| Intangibles / total assets | 23.8% | 26.2% | 25.1% | 27.5% | 30.4% | 32.8% | 34.1% | 39.4% |
Computed from GRDN's annual financial statements (latest annual report filed March 11, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
GRDN valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Guardian Pharmacy Services traded at 38.7 times earnings. Based on the latest twelve months, the trailing P/E is 38.3 and the forward P/E is 30.2. Guardian Pharmacy Services earned a return on equity of 28.3% and a return on invested capital of 34.3% in fiscal 2025. It ended the year with $37.1 million of debt and $65.6 million in cash and short-term investments, a net cash position of $28.5 million. It returned $29.0 million to shareholders: $0 in dividends and $29.0 million in share buybacks, 36% of free cash flow. The share count rose 4.0% from 60.8M to 63.3M over 7 years.
See the GRDN income statement, the GRDN chart for price history, or the GRDN stock overview for the latest quote and news.
GRDN key metrics FAQ
What is Guardian Pharmacy Services's P/E ratio?
Guardian Pharmacy Services's trailing P/E ratio is 38.3 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 30.2. At the end of fiscal 2025 it was 38.7.
What is Guardian Pharmacy Services's EV/EBITDA?
Guardian Pharmacy Services's enterprise value was 19.5 times EBITDA at the end of fiscal 2025 (enterprise value $1.9 billion, EBITDA $96.4 million); the current EV/EBITDA is 22.4.
What is Guardian Pharmacy Services's return on equity?
Guardian Pharmacy Services's return on equity (ROE) was 28.3% in fiscal 2025: net income of $49.2 million on average shareholders' equity of $174.2 million.
What is Guardian Pharmacy Services's ROIC?
Guardian Pharmacy Services's return on invested capital was 34.3% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Guardian Pharmacy Services have?
Guardian Pharmacy Services had total debt of $37.1 million at the end of fiscal 2025, a debt-to-equity ratio of 0.18 and more cash than debt.
Does Guardian Pharmacy Services pay a dividend?
Guardian Pharmacy Services did not pay a dividend in fiscal 2025.
Does Guardian Pharmacy Services buy back its shares?
Yes. Guardian Pharmacy Services spent $29.0 million on net share repurchases in fiscal 2025 Shares outstanding changed +2.1% over the year, to 63.3M..
What is Guardian Pharmacy Services's free cash flow yield?
Guardian Pharmacy Services generated $80.7 million of free cash flow in fiscal 2025, a free cash flow yield of 4.2% on its market value at year-end ($1.9 billion).
What is Guardian Pharmacy Services's current ratio?
Guardian Pharmacy Services's current ratio was 1.38 at the end of fiscal 2025: current assets were 1.38 times current liabilities.